PE20080176A1 - Compuestos de arilpiperazina sulfonamida como agonista de los receptores de secretagogos de la hormona de crecimiento (ghs) - Google Patents

Compuestos de arilpiperazina sulfonamida como agonista de los receptores de secretagogos de la hormona de crecimiento (ghs)

Info

Publication number
PE20080176A1
PE20080176A1 PE2007000359A PE2007000359A PE20080176A1 PE 20080176 A1 PE20080176 A1 PE 20080176A1 PE 2007000359 A PE2007000359 A PE 2007000359A PE 2007000359 A PE2007000359 A PE 2007000359A PE 20080176 A1 PE20080176 A1 PE 20080176A1
Authority
PE
Peru
Prior art keywords
arilpiperazine
ghs
receptors
growth hormone
agonist
Prior art date
Application number
PE2007000359A
Other languages
English (en)
Inventor
Emma Louise Blaney
Nigel Paul King
Jason Witherington
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0606526A external-priority patent/GB0606526D0/en
Priority claimed from GB0704766A external-priority patent/GB0704766D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20080176A1 publication Critical patent/PE20080176A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

SE REFIERE A COMPUESTOS DE ARILPIPERAZINA SULFONAMIDA DE FORMULA (I), EN DONDE Ra ES ARILO O HETEROARILO OPCIONALMENTE SUSTITUIDOS; Rb Y Rc SON INDEPENDIENTEMENTE H O ALQUILO(C1-C6); Q ES UN ANILLO EN EL QUE W y X SON INDEPENDIENTEMENTE CH O N; Y y Z SON INDEPENDIENTEMENTE CRd o N; Rd ES H, ALQUILO(C1-C6), ALCOXI(C1-C6), HALOGENO, ENTRE OTROS; EN DONDE AL MENOS UNO DE Rb y Rc ES ALQUILO(C1-C6) Y AL MENOS UNO DE W, X, Y y Z ES N. SON PREFERIDOS: N-{6-[CIS-3,5-DIMETIL-1-PIPERAZINIL]-2-PIRIDINIL}-3-FLUORO-4-(5-METIL-2-FURANIL)BENCENOSULFONAMIDA, 2-CLORO-N-[6-(3R,5S)-3,5-DIMETIL-1-PIPERAZINIL]-3-(METILOXI)-2-PIRIDINIL]-4-(3-FURANIL)BENCENOSULFONAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON AGONISTAS SELECTIVOS DE LOS RECEPTORES DE SECRETAGOGOS DE LA HORMONA DE CRECIMIENTO (GHS), POR LO QUE SON UTILES EN EL TRATAMIENTO DE TRASTORNOS GASTROINTESTINALES Y RELACIONADOS
PE2007000359A 2006-03-31 2007-03-29 Compuestos de arilpiperazina sulfonamida como agonista de los receptores de secretagogos de la hormona de crecimiento (ghs) PE20080176A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0606526A GB0606526D0 (en) 2006-03-31 2006-03-31 Novel compounds
GB0704766A GB0704766D0 (en) 2007-03-12 2007-03-12 Novel compounds

Publications (1)

Publication Number Publication Date
PE20080176A1 true PE20080176A1 (es) 2008-04-25

Family

ID=38110118

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000359A PE20080176A1 (es) 2006-03-31 2007-03-29 Compuestos de arilpiperazina sulfonamida como agonista de los receptores de secretagogos de la hormona de crecimiento (ghs)

Country Status (7)

Country Link
US (1) US7713978B2 (es)
EP (1) EP2013178A1 (es)
JP (1) JP2009531385A (es)
AR (1) AR060213A1 (es)
PE (1) PE20080176A1 (es)
TW (1) TW200808709A (es)
WO (1) WO2007113202A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007118900A1 (en) * 2006-04-19 2007-10-25 Abbott Gmbh & Co. Kg Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
EP2211615A4 (en) * 2007-10-22 2010-10-13 Glaxosmithkline Llc PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011078143A1 (ja) * 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
PT2550269E (pt) * 2010-03-23 2016-06-20 Scinopharm Taiwan Ltd Processo e intermediários para a preparação de lapatinib
MX2017006205A (es) 2014-11-12 2017-11-17 Lyric Pharmaceuticals Inc Tratamiento de la intoleracia a la alimentacion enteral.
WO2017083882A1 (en) * 2015-11-11 2017-05-18 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance and other conditions using ulimorelin analogs

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9803411D0 (en) 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
CN1309654A (zh) 1998-07-20 2001-08-22 默克专利股份有限公司 联苯基衍生物
HUP0202787A3 (en) 1999-09-25 2003-12-29 Smithkline Beecham Plc Piperazine derivatives as 5-ht1b antagonists, process for their preparation and pharmaceutical compositions containing them
ES2290115T3 (es) 2000-02-01 2008-02-16 ABBOTT GMBH & CO. KG Compuestos heterociclicos y su aplicacion como inhibidores de parp.
EP1259485B1 (en) 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
BR0115102B1 (pt) 2000-11-02 2013-11-26 Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos
CN1289072C (zh) 2000-12-22 2006-12-13 石原产业株式会社 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂
GB0106419D0 (en) 2001-03-15 2001-05-02 Smithkline Beecham Plc Novel compounds
GB0106586D0 (en) 2001-03-16 2001-05-09 Smithkline Beecham Plc Novel compounds
JP4445262B2 (ja) 2001-10-09 2010-04-07 アムジェン インコーポレイテッド 抗炎症剤としてのイミダゾール誘導体
DE60221627D1 (de) 2001-12-21 2007-09-20 Virochem Pharma Inc Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
JP3985526B2 (ja) * 2002-01-16 2007-10-03 松下電器産業株式会社 磁気回路およびこの磁気回路を用いたスピーカ
US6747419B2 (en) * 2002-07-03 2004-06-08 Ushio America, Inc. Method and apparatus for heat pipe cooling of an excimer lamp
EP1572212A2 (en) 2002-12-11 2005-09-14 7TM Pharma A/S Quinoline compounds for use in mch receptor related disorders
WO2004076413A2 (en) 2003-02-24 2004-09-10 Arena Pharmaceuticals, Inc. Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism
AR043633A1 (es) * 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
WO2004087653A2 (en) 2003-04-03 2004-10-14 Merck & Co., Inc. 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5
US20040204422A1 (en) * 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
US7320979B2 (en) * 2003-04-14 2008-01-22 Abbott Gmbh & Co. Kg. N-[(piperazinyl)hetaryl]arylsulfonamide compounds
AU2004259024B2 (en) 2003-07-23 2011-06-23 Synta Pharmaceuticals, Corp. Compounds for inflammation and immune-related uses
WO2005040109A1 (en) 2003-10-22 2005-05-06 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
EP1753740A2 (en) 2004-05-21 2007-02-21 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
DE102004028973A1 (de) 2004-06-16 2006-01-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
US7381728B2 (en) * 2004-07-28 2008-06-03 Glaxo Group Limited Piperazine derivatives useful for the treatment of gastrointestinal disorders
US7282506B2 (en) * 2004-08-03 2007-10-16 Serenex, Inc. 2,8-disubstituted naphthyridine derivatives
WO2006034446A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
DE102005015040A1 (de) 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament

Also Published As

Publication number Publication date
US7713978B2 (en) 2010-05-11
AR060213A1 (es) 2008-06-04
TW200808709A (en) 2008-02-16
EP2013178A1 (en) 2009-01-14
US20070238737A1 (en) 2007-10-11
WO2007113202A1 (en) 2007-10-11
WO2007113202A8 (en) 2008-01-17
JP2009531385A (ja) 2009-09-03

Similar Documents

Publication Publication Date Title
PE20080176A1 (es) Compuestos de arilpiperazina sulfonamida como agonista de los receptores de secretagogos de la hormona de crecimiento (ghs)
PE20060574A1 (es) Derivados de arilpiperazina sulfonamida como agonistas de los receptores de secretagogos de la hormona del crecimiento (ghs)
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
PE20091204A1 (es) Derivados de 2-aminoquinolina como antagonistas del receptor de 5-ht5a
PE20141110A1 (es) Derivados heterociclicos novedosos para el tratamiento de trastornos neurologicos
PE20070706A1 (es) Nuevos derivados imidazopiridina como antagonistas de adenosina a2b
PE20090437A1 (es) Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos
PE20060150A1 (es) Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion
PE20070016A1 (es) Compuestos heterociclicos n-enlazados como antagonistas del receptor p2y1
PE20120937A1 (es) Compuestos derivados de quinolina y quinoxalina como agentes antivirales
PE20060334A1 (es) Derivados de piridina como antagonistas del receptor a2b de adenosina
PE20060501A1 (es) Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa
EA200601364A1 (ru) Производные хинолина и их применение в качестве ингибиторов микобактерий
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
PE20141042A1 (es) Nuevos derivados biciclicos de dihidroquinolina-2-ona
AR080688A1 (es) Derivados de 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.5]nonano como agonistas o antagonistas inversos de grelina
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
DK1716152T3 (da) Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20060691A1 (es) Serinamidas sustituidas por benzoilo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal